Navigation Links
JumpStart Invests $250,000 in Milo Biotechnology
Date:2/14/2012

CLEVELAND, Feb. 14, 2012 /PRNewswire/ -- Milo Biotechnology will receive $250,000 from JumpStart Inc., a nonprofit investing intensive business assistance and some capital into early stage Northeast Ohio-based tech companies.  A clinical stage startup developing a therapy to increase muscle strength and improve the quality of life of muscular dystrophy patients, Milo is the 61st company in JumpStart's portfolio.  "There are limited treatment options for muscular dystrophy and approved therapies are inadequate or can cause significant side effects," says JumpStart's Mike Lang. "Since most muscular dystrophy patients are children, the medical community is interested in a safer and more targeted therapy."

Milo Biotechnology's lead product is an adeno-associated virus (AAV) delivered follistatin protein.  Follistatin inhibits the activity of myostatin, a protein that impedes muscle differentiation and growth.  That makes follistatin a very potent stimulator of muscle growth and prevention of muscle scarring after injury.  "The translational research team at the Research Institute at Nationwide Children's Hospital has harnessed the power of follistatin and increased its specificity for muscle," explains Al Hawkins, CEO of Milo Biotechnology and CEO-in-Residence at BioEnterprise in Cleveland. "The efficacy and safety results thus far have been remarkable." Pre-clinical studies in mice and non-human primates demonstrated considerable increases in muscle size and strength.  FDA approved the investigators' IND in October 2011 and a clinical trial evaluating the safety and efficacy of Milo's follistatin therapy began last month at Columbus-based Nationwide Children's Hospital, where the technology was developed.  The Phase I/II trial, funded by a grant from Parent Project Muscular Dystrophy, is enrolling patients with Becker muscular dystrophy and inclusion body myositis.

Milo Biotechnology was founded by Hawkins and one of the lead inventors of the follistatin technology, Brian Kaspar, PhD. 

MILO BIOTECHNOLOGY  Milo Biotechnology is a Cleveland-based company dedicated to improving the lives of patients with neuromuscular diseases.  Milo's early clinical stage follistatin program, exclusively licensed from Nationwide Children's Hospital, is designed to increase muscle size and strength.

JUMPSTART INC  JumpStart Inc. accelerates the successes of entrepreneurs, their companies, and the ecosystems supporting them. JumpStart has given intensive business assistance to more than 400 entrepreneurial clients and invested in 61 early stage Northeast Ohio companies. For more information, visit www.jumpstartinc.org and follow @JumpStartInc on Twitter.


'/>"/>
SOURCE JumpStart Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
2. Lockheed Martin Invests in Smart Grid Research and Development at Penn State University
3. Burrill & Company Invests in Taiwan Liposome Company
4. University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer
5. The Pittsburgh Life Sciences Greenhouse Invests $725K in Portfolio Companies
6. Syngenta Ventures Invests in U.S. Biotech Company Metabolon
7. BioCrossroads Indiana Seed Fund Invests in Vaccine Biotech Company
8. BR Ventures Invests in Semprae Laboratories
9. BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimers Disease
10. Federal grant invests in nanostructured super materials
11. BioCrossroads Invests in Innovative Biotech Targeting Challenging Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Alex,s Lemonade ... announced that that it will open a state-of-the-art bioinformatics ... childhood cancer research. This announcement comes as Liz ... attends the National Cancer Moonshot Summit in ... Dr. Biden as a participant and advocate of pediatric ...
(Date:6/27/2016)... , June 27, 2016  Global demand ... 4.6 percent through 2020 to $7.2 billion.  This ... and beverages, cleaning products, biofuel production, animal feed, ... biotechnology, diagnostics, and biocatalysts). Food and beverages will ... driven by increasing consumption of products containing enzymes ...
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
Breaking Biology Technology:
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... June 22, 2016  The American College of Medical Genetics ... Executive Magazine as one of the fastest-growing trade shows ... at the Bellagio in Las Vegas . ... percentage of growth in each of the following categories: net ... and number of attendees. The 2015 ACMG Annual Meeting was ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
Breaking Biology News(10 mins):